MX2010006521A - Metodo y composicion para el tratamiento de una condicion mediada por el receptor de serotonina. - Google Patents

Metodo y composicion para el tratamiento de una condicion mediada por el receptor de serotonina.

Info

Publication number
MX2010006521A
MX2010006521A MX2010006521A MX2010006521A MX2010006521A MX 2010006521 A MX2010006521 A MX 2010006521A MX 2010006521 A MX2010006521 A MX 2010006521A MX 2010006521 A MX2010006521 A MX 2010006521A MX 2010006521 A MX2010006521 A MX 2010006521A
Authority
MX
Mexico
Prior art keywords
composition
treating
serotonin receptor
mediated condition
mediated
Prior art date
Application number
MX2010006521A
Other languages
English (en)
Inventor
Mihael H Polymeropoulos
Curt D Wolfgang
Paolo Baroldi
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of MX2010006521A publication Critical patent/MX2010006521A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen un método y composición para el tratamiento de condiciones mediadas por el receptor de serotonina.
MX2010006521A 2007-12-13 2008-12-13 Metodo y composicion para el tratamiento de una condicion mediada por el receptor de serotonina. MX2010006521A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1337707P 2007-12-13 2007-12-13
PCT/US2008/086734 WO2009076664A1 (en) 2007-12-13 2008-12-13 Method and composition for treating a serotonin receptor-mediated condition

Publications (1)

Publication Number Publication Date
MX2010006521A true MX2010006521A (es) 2010-08-10

Family

ID=40350212

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006521A MX2010006521A (es) 2007-12-13 2008-12-13 Metodo y composicion para el tratamiento de una condicion mediada por el receptor de serotonina.

Country Status (17)

Country Link
US (3) US8618134B2 (es)
EP (1) EP2222300B1 (es)
JP (2) JP2011506482A (es)
AU (1) AU2008334933B2 (es)
BR (1) BRPI0821131A2 (es)
CA (1) CA2709104C (es)
CY (1) CY1115587T1 (es)
DK (1) DK2222300T3 (es)
ES (1) ES2483366T3 (es)
HR (1) HRP20140701T1 (es)
MX (1) MX2010006521A (es)
NZ (1) NZ585923A (es)
PL (1) PL2222300T3 (es)
PT (1) PT2222300E (es)
SI (1) SI2222300T1 (es)
WO (1) WO2009076664A1 (es)
ZA (1) ZA201004213B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2222301B1 (en) 2007-12-13 2014-10-08 Vanda Pharmaceuticals Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
WO2009076664A1 (en) * 2007-12-13 2009-06-18 Vanda Pharmaceuticals Inc. Method and composition for treating a serotonin receptor-mediated condition
MX2012007365A (es) 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772475A (en) 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5364866A (en) 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
GB9611356D0 (en) 1996-05-31 1996-08-07 Howard Alan N Improvements in or relating to compositions containing Creatine, and other ergogenic compounds
US5968554A (en) 1998-07-07 1999-10-19 Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc. Sustained release pharmaceutical preparation
US6312728B1 (en) 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
DK1425272T3 (da) 2001-08-31 2011-11-21 Novartis Ag Optiske isomerer af en iloperidon-metabolit
US6500454B1 (en) 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
CN101912367A (zh) 2001-10-30 2010-12-15 诺瓦提斯公司 伊潘立酮和星状聚合物的贮库制剂
CA2468972A1 (en) 2001-12-10 2003-07-03 Novartis Ag Methods of treating psychosis and schizophrenia based on a polymorphism in the cntf gene
US6663888B2 (en) 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
CN1826322B (zh) * 2003-07-22 2012-04-18 艾尼纳制药公司 用于预防和治疗相关病症而作为5-ht2a血清素受体调节剂的二芳基和芳基杂芳基脲衍生物
CA2582022C (en) * 2004-09-30 2021-05-18 Vanda Pharmaceuticals, Inc. Methods for the administration of iloperidone
SA05260357B1 (ar) * 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
DE102005016981A1 (de) 2005-04-13 2006-10-19 Bayer Healthcare Ag Kombination zur Therapie bei benigner Prostatahyperplasie
EP2222301B1 (en) * 2007-12-13 2014-10-08 Vanda Pharmaceuticals Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
WO2009076664A1 (en) * 2007-12-13 2009-06-18 Vanda Pharmaceuticals Inc. Method and composition for treating a serotonin receptor-mediated condition

Also Published As

Publication number Publication date
EP2222300A1 (en) 2010-09-01
US20110044971A1 (en) 2011-02-24
BRPI0821131A2 (pt) 2017-10-03
CA2709104C (en) 2017-06-13
US9987264B2 (en) 2018-06-05
HRP20140701T1 (hr) 2014-11-21
US9446038B2 (en) 2016-09-20
ES2483366T3 (es) 2014-08-06
WO2009076664A1 (en) 2009-06-18
DK2222300T3 (da) 2014-07-21
PT2222300E (pt) 2014-07-28
CA2709104A1 (en) 2009-06-18
JP2011506482A (ja) 2011-03-03
EP2222300B1 (en) 2014-06-11
US20160361303A1 (en) 2016-12-15
US8618134B2 (en) 2013-12-31
US20140079685A1 (en) 2014-03-20
NZ585923A (en) 2012-09-28
PL2222300T3 (pl) 2015-02-27
CY1115587T1 (el) 2017-01-04
SI2222300T1 (sl) 2014-11-28
AU2008334933B2 (en) 2016-01-21
JP5925862B2 (ja) 2016-05-25
JP2015051991A (ja) 2015-03-19
AU2008334933A1 (en) 2009-06-18
ZA201004213B (en) 2012-11-28

Similar Documents

Publication Publication Date Title
IL257418A (en) Methods for treating addiction
EP2384221A4 (en) METHOD FOR REDUCING COMPLAINTS DURING ELECTROSTIMULATION AND COMPOSITIONS AND DEVICE THEREFOR
EP2019675A4 (en) METHODS FOR TREATING OR PREVENTING NEOPLASIA
AP2009004851A0 (en) Compositions and methods for diagnosing, treating,and preventing prostate conditions
PL2191901T3 (pl) Młynek drobnomielący i sposób jego stosowania
IL208027A0 (en) Methods, compositions, and kits for treating pain and pruritus
SG148142A1 (en) Aryloazol-2-yl cyanoethylamino compunds, method of making and method of using thereof
EP2179537A4 (en) METHOD AND APPARATUS FOR COMMUNICATION AND METHOD AND APPARATUS FOR COMMUNICATION CONTROL
EP2233443A4 (en) HEATING DEVICE FOR GLASS SHEET MOLDING AND BENDING SHEET METHOD FOR GLASS WASHERS
SG139652A1 (en) Laser marking method
EP2214776A4 (en) Apparatus for treating impotence
MX2010008093A (es) Proceso para la hidrogenacion de pentafluoropropeno.
SG143149A1 (en) Phosphite composition and method for producing the same
AP2011005581A0 (en) Method and apparatus for refining coal.
PL2441462T3 (pl) Sposób leczenia cukrzycy typu I
TWI319547B (en) Method for generating typographical line
HK1140967A1 (en) Vesicle-containing composition, and method for production thereof
MX2009009822A (es) Composiciones y metodos para reducir niveles de h2s en bebidas fermentadas.
MX2010006521A (es) Metodo y composicion para el tratamiento de una condicion mediada por el receptor de serotonina.
EP2035037A4 (en) METHOD, COMPOSITIONS AND KITS FOR TREATING SHIGA-TOXIN ASSOCIATED ILLNESSES
HK1135507A1 (en) Resin-bleedout preventing agent and method for preventing resin-bleedout, and substrate
EP2180255A4 (en) WASTE SUPPLY DEVICE, METHOD OF SEPARATING AND WASTE TRANSFER METHOD
AU2018256496A1 (en) Method and composition for treating a serotonin receptor-mediated condition
ZA201004212B (en) Method and composition for treating an alpha adrenoceptor-mediated condition
EP2102387A4 (en) PROCESS FOR HEATING ANODE BLOCKS AND ARRANGEMENT FOR HEATING ANODE BLOCKS

Legal Events

Date Code Title Description
FG Grant or registration